Proteostasis shares jumped on Wednesday after the firm announced positive, initial ex-vivo results of its proprietary cystic fibrosis transmembrane conductance regulator modulators, PTI-801, PTI-808 and PTI-428.
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
A new study indicates that the individual mandate portion of the Affordable Care Act (Obamacare) did encourage more people to get insurance coverage. And some Americans will live longer because of it.
Dermira shares jumped on Tuesday after the firm announced that the FDA has granted Fast Track designation for lebrikizumab, its treatment moderate-to-severe atopic dermatitis.
Some sick Americans have probably become sicker because they do not believe they can pay for appropriate treatment. And the trend has spiked in the past year.
Fate Therapeutics shares jumped on Monday after the firm announced new preclinical data for its off-the-shelf, multi-antigen targeting natural killer cell product candidate derived from a clonal master engineered induced pluripotent stem cell line.
Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a few of these standouts…
Protagonist Therapeutics shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia.
Audentes Therapeutics shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just over three years, this acquisition offers a…
Aslan Pharmaceuticals has been on a roller coaster for the past two weeks. Now the stock is coming back to earth, with the company announcing that it will be capitalizing on these gains with…